Asset Management One Co. Ltd. lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 8.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,178,000 shares of the medical research company’s stock after selling 114,603 shares during the period. Asset Management One Co. Ltd.’s holdings in Amgen were worth $193,296,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Camber Capital Management LLC bought a new position in Amgen during the fourth quarter valued at $43,863,000. Israel Discount Bank of New York GFN bought a new position in Amgen during the fourth quarter valued at $253,000. Dodge & Cox bought a new position in Amgen during the fourth quarter valued at $5,732,000. Lincoln Capital Corp bought a new position in Amgen during the fourth quarter valued at $2,398,000. Finally, Aldebaran Financial Inc. boosted its position in Amgen by 1.6% in the fourth quarter. Aldebaran Financial Inc. now owns 8,302 shares of the medical research company’s stock valued at $1,214,000 after buying an additional 129 shares during the last quarter. 79.12% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 167.29 on Friday. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The stock has a market cap of $122.07 billion, a PE ratio of 15.24 and a beta of 1.35. The stock’s 50 day moving average price is $174.04 and its 200 day moving average price is $168.05.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.84 EPS. On average, equities research analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be given a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.75%. Amgen’s payout ratio is 41.93%.
Several research analysts have recently weighed in on AMGN shares. Sanford C. Bernstein reissued a “market perform” rating and set a $178.00 price objective on shares of Amgen in a report on Tuesday, April 25th. Cowen and Company restated a “buy” rating and set a $209.00 target price on shares of Amgen in a research report on Thursday, April 27th. Robert W. Baird restated a “neutral” rating and set a $165.00 target price on shares of Amgen in a research report on Friday, April 28th. Mizuho set a $195.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Saturday, May 6th. Finally, Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the stock a “buy” rating in a research report on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. Amgen currently has a consensus rating of “Buy” and a consensus price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.20% of the stock is currently owned by company insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.